Working inthe Centauri lab

Revolutionising immunotherapy for the most vulnerable patients through our novel Alphamer® technology.

Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

Latest News and Articles

Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections

March 10, 2026

See attached press release

Read More
Centauri Theraputics Main Logo

Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate

February 24, 2026

See attached press release

Read More

Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

July 29, 2025

See attached press release

Read More